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COolanoP 15 (formerly designated MCS la), a synthetic heat transfer fluid, 
is currently being used in the heat transfer systems of manned s p a d  The 
current studies were undertaken to wdrm or refute previously reported &ects 
on the central nervous system and to acquire additional information on the 
and rats, repeated subcutane~~s injections in rabbits, and the repeated cutaneous 
application on the unabraded skin of rabbits, monkeys, and dogs were invesli- 
gated. Parenteral injection revealed that coolawl 15 is relatively nontoxic. The 
for mice was found to be greater than 20.0 gm (22.2 ml) per kg at 24 
hours and 5.9 gm (6.6 ml) per kg at 7 and 14 days. Repeated s u b c u m u s  
injections in rabbits resulted primarily in localized reactions at injection sites. 
The only efEects which could be directly attributed to the cutaneous application 
of 3.6 gm (4.0 ml) per kg per day for 20 days involved the skin. Drying and 
encrustation and/or desquamation of the superficial layers of the skin were the 
principal lesions observed clinically, while microscopic examination revealed 
varying degrees of hyperkeratosis and cellular inliltration. These studies failed 
to confinm the previously reported lesions in the central nervous system attributed 
to coolawl 1s. 
toxkity of this compound. The effects of single intrapexitoneal injections in mice 
I 
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SECTION I 
Introduction 
Coolanol@ 15 ( formerly designated MCS 198), a synthetic heat-transfer fluid developed by 
the Monsanto Company, St. Louis, Missouri, is currently being used in the heat transfer systems 
of manned spacecraft. Since astronauts could be exposed to the fluid if equipment failure resulted 
in its release into the air-conditioning system of the cabin or space suits, a knowledge of the 
toxicity of the compound is of vital importance. Unpublished data received by the National 
Aeronautics and Space Adminisbation revealed focal changes in the central nervous system of 
rabbits that received cutaneous applications of 1.5 and 2.5 ml/kg daily for 20 days. These changes 
consisted of nodular glial and ependymal proliferations, pigment deposits and perivascular 
lymphocytic infiltration, and were believed to be related to the Coolanol 15. Lesions were not 
observed, however, in animals that had received daily applications of 4.0 ml/kg. 
In this investigation, acute and subacute parenteral administration studies and a subacute 
cutaneous application study were completed in several species of animals. These were under- 
taken to conhm or refute the previously reported effects on the central nervous system and to 
acquire additional information on the toxic properties of this compound. 
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SECTION I I  
Acute Toxicity 
METHOD 
Male Swiss mice weighing between 15.5 and 27.5 grams were given Coolanol 15 by intra- 
peritoneal injection at dose levels varying between 2.5 and 20.0 gm/kg (2.8 to 22.2 ml/kg). In 
addition, a preliminary screening of the dose response was accomplished in male Sprague-Dawley 
strain rats weighing between 160 and 255 grams. During the course of the study, the animals 
were individually housed in hanging wire mesh cages. Rockland Mouse/Rat Diet and tap water 
were available ad libitum. 
RESULTS 
MZCE 
The ratios of deaths to number of animals injected were as follows: 
Dose - gm/kg 
Time Observed 2.5 3.5 5.0 5.7 7.1 10.0 20.0 
24 hours 0/5 1/25 0/30 0/15 0/25 0/5  0/5 
7 days 0/5 4/25 8/30 7/15 16/25 5/5 4/5 
14 days -- 4/25 8/25 7/15 17/25 -- -- 
The following LDSO values and slope functions and their respective 95% confidence intervals 
were determined using the method of Litchfield and Wilcoxon*. 
Time LDSO Slope Function 
24 hours >20.0 gm/kg -- 
7 days 5.90 gm/kg (5.09 - 6.84) 1.67 (1.40 - 1.99) 
14 days 5.90 gm/kg (5.00 - 6.96) 1.62 (1.15 - 2.28) 
Clinical observations included some reduction in activity following injection, loose stools, 
anorexia, slight hyperexcitability when disturbed, slight ocular discharge, and some degree of 
photophobia. Improvement was observed in 3 to 6 days in affected animals that lived. 
Necropsies were performed on five mice that died between 72 and 120 hours postinjec- 
tion at doses ranging from 3.5 to 7.07 gm/kg. All exhibited generalized autolytic changes which 
complicated the examination. In general, however, there was congestion, edema or hemorrhage, 
and cellular infiltration in the lungs. Granular cast formation and degenerative tubular changes 
were seen in the kidneys. One animal had a small glial focus in the cerebral cortex. This was 
probably due to an infection by Encephalitozoon sp. or similar organism and not related to the 
Coolanol 15 injection. 
* Litchfield, J. T., Jr. and F. Wilcoxon, “A Simple Method of Evaliiating Dose-Effect Experiments,” J .  Phurmncol. 
Exptl. Therap., 96: 99-113, 1949. 
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c -  RATS 
The ratios of deaths to number of animals injected were as follows: 
Dose - gm/kg 
Time Observed 25 5.0 10.0 20.0 
24 hours 0/5 0/5 0/5 0/4 
7 days 0/5 0/5 5/5 4/4 
Clinical observations were similar to those seen in mice but also included a ~ ~ a l  discharge. 
A moderate weight loss was noted in animals that survived. 
Necropsies were performed on three animals that died and one animal that was killed in 
a terminal state between 3 and 11 days postinjection. Lesions observed included marked gen- 
eralized peritonitis, toxic tubular nephritis, and congestion of the liver with inward extension of 
perihepatitis. Spontaneous lesions not related to the Coolanol 15 injection included bilateral otitis 
media and mild chronic murine pneumonia. One animal that exhibited symptoms of a central 
nervous system disturbance before death had mild lymphocytic infiltrations and scant hemorrhage 
in the leptomeninges and focal hemorrhagic encephalomalacia in the temporal cortex which ap- 
peared to be of infectious etiology. 
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SECTION 111 
Subacute Toxicity 
METHOD 
Two albino rabbits each weighing 2.0 kg, were given subcutaneous injections of Coolanol 15 
for 14 days. Two-day intervals separated injection periods of 5, 5, and 4 days. Eight injection 
sites, four on each side, located lateral to the dorsal midline were used. A dose of 270 mg (0.30 
ml) per kg was given daily for the first 5-day period. This was increased to 540 mg (0.6 ml) 
per kg during the remaining periods. The two treated animals and one control animal that had 
been given saline were killed by an intravenous injection of pentobarbital sodium on the fourth 
day following the last injection. The animals were housed in individual cages and given Purina 
Rabbit Chow and tap water ad libitum during the course of the study. 
RESULTS 
Significant clinical manifestations were limited to local reactions at the injection sites. These 
ranged from little or no reaction to erythema, edema, induration, and abscess formation. Only 
mild reactions were observed when the Coolanol 15 dispersed rapidly. The inconsistent response 
at injection sites apparently resulted from differences in the subcutaneous tissue plane in which 
the liquid was deposited. 
The Coolanol 15 used for injection was bacteriologically negative when cultured in thiogly- 
collate broth and on blood agar and EMB plates. 
The principal lesions observed at necropsy were multiple subcutaneous abscesses at injection 
sites in the animals that received Coolanol 15. Bacteriologic cultures of abscess contents were 
negative. Both rabbits had scattered foci of purulent pneumonia, and mild inflammatory foci 
were present in the portal areas of the liver. A section of the thoracic spinal cord from one 
animal revealed an organizing cellular mass in the central canal which did not appear to be the 
result of the Coolanol 15 administration. No other lesions were observed in the central nervous 
system of either animal. 
at the injection sites and a few scattered granulomata of infectious etiology in the liver. 
The only lesions observed in the control animal were petechiae in the subcutaneous tissues 
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SECTION IV 
Cutaneous Application 
MEmoD 
coolano1 15 was applied to the unabraded skin of four albino rabbits, four MQCUCU mukzttu 
mo+s, and four mongrel dogs. Applications were made 5 days per week for 4 weeks, making a 
total of 20 days of application. The amount of Coolanol 15 applied was 4.0 mlkg  body weight 
per day with tbe volume adjusted to the body weight at the beginning of each weekly application 
period. The daily dose was divided into 4 separate applications of 1.0 ml/kg each which were 
applied at appximately 0830, 0930, 1430, and 1530 hours. This was done in an attempt to 
limit the application area to about 1096 of the total body surface and was based on the results of 
prelimimry trials on rabbits with dye added to the compound. Distilled water was applied to two 
control animals of each species. Glass syringes with blunted Wgauge needles were used to spray 
the Coolano1 15 or distilled water on the skin surface. Application was made along the dorsal 
midline from about midscapula to the sacral area. The monkeys were held in a horizontal posi- 
tion during the application. From 10 to 15 minutes were required to treat all 18 experimental 
and control animals. 
The backs and sides of all animals were clipped before the fist application of Coolanol 15. 
Due to the rapid spread of the compound, the chest and abdomen of the monkeys were also 
clipped at the beginning of the second weekly application period. All animals were reclipped 
as necessary at the time body weights were obtained each week. 
Body weights were obtained by having a caretaker hold the animals while standing on a 
The animaln were housed in individual cages during the course of the study. Water was 
available ad libitum. Dogs were fed Teklad Dog Diet with m k e d  or canned horsemeat twice 
daily, monkeys were given Purina Monkey Chow twice daily supplemented with fruit or vege- 
tables in the afternoon, and rabbits had purina Rabbit Chow available ad libitum. 
On the third day following the final application, all surviving animals were killed with an 
At necropsy, gross observations were recorded and tissues from the major organ systems 
were fixed in bdfered formalin for subsequent microscopic examination. In addition, skin speci- 
mens from the shoulder, dorsal thoracic and lumbar areas, and flank were obtained and marked 
for identi6cation. The entire brain and portions of the cervical, thordcic and lumbar spinal card 
were also saved for examination. The brain was sliced grossly at 05 to 1.0 cm intervals. Portions 
of alternate slices of the brain and all other tissues were p d  and stained with hematoxylin 
and eosin. In addition, selected sections from four areas of the brain and the thoracic and lumbar 
spinal cord of selected animals were stained with Lux01 Fast Blue-cresyl violet. Frozen sections of 
two areas of the brain and the cervical spinal cord were prepared from fixed tissue from the same 
animals. These were stained by Cajal’s gold sublimate method for the demonstration of astrocytes. 
physician’s office scale and subtracting the caretaker’s weight from the gross weight obtained. 
overdose of pentobarbital sodium administered intravenously and necropsies were performed. 
RESULTS 
The coolano) 15 spread rapidly over the skin surface even when applied in a narrow band 
along the dorsal midline. The rapidity and extent of the spread on monkeys and dogs was con- 
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siderably greater than anticipated. By the time the monkeys were returned to the cage, the Cool- 
anol 15 had generally spread completely around the body. There was some spread down the 
legs if the animal was held in a vertical position after application or stood in an upright position 
when returned to its cage. The second application in the morning or afternoon frequently spread 
to the ventral midline of dogs within 15 minutes. On the rabbits, the Coolanol 15 rarely spread 
beyond the clipped area which involved approximately 15% of the body surface. Skin lesions 
which developed, particularly on the rabbits, inhibited the spread. 
Some licking of the skin surface occurred following the application of Coolanol 15. This was 
observed most frequently in the rabbits and occasionally in the dogs. 
There apparently was some irritative sensation immediately after the application of Cool- 
anol 15. This was most pronounced after the appearance of skin lesions. Beginning with the sec- 
ond weekly application period, rabbits made definite efforts to escape from restraint while the 
substance was being applied or immediately after application. This was also seen in monkeys 
and dogs to some degree although the relationship between skin lesions and escape reaction 
was less definite. 
The following body weight data were obtained during the study: 
Body Weight - kg 
Animal Sf% 8 Mar(a) 15 Mar 22 Mar 23 Mar 5Apr(b) 
Rabbits 
A16 
A18 
A20 
A24 
A14(c) 
Monkeys 
A31 
A33 
A43 
A45 
A37( c) 
A47(c) 
Dogs 
B31 
B61 
C60 
c84 
B13(c) 
C82( c) 
AWc) 
M 
M 
M 
M 
M 
M 
F 
F 
F 
F 
F 
F 
F 
F 
M 
M 
F 
M 
2.0 
1.9 
2.0 
2.5 
2.4 
2.0 
2.3 
2.2 
2.4 
2.5 
1.9 
2.4 
6.4 
11.4 
9.1 
9.5 
9.1 
9.5 
2.0 
2.0 
2.6 
2.5 
2.5 
2.5 
2.2 
2.4 
2.4 
2.4 
2.2 
2.3 
6.5 
10.9 
8.6 
10.0 
9.9 
10.0 
1.8 
1.7 
2.4 
2.3 
2.6 
2.4 
2.1 
2.3 
2.3 
2.5 
1.9 
2.3 
6.1 
10.7 
8.5 
9.3 
9.3 
10.0 
( 4  
1.8 
2.3 
2.5 
2.5 
2.6 
2.3 
2.3 
2.0 
2.5 
2.0 
2.3 
7.0 
11.4 
9.0 
9.5 
9.5 
9.9 
- 
1.7 
2.2 
2.5 
2.6 
2.8 
2.2 
2.0 
2.0 
2.2 
2.0 
2.3 
6.4 
10.7 
8.4 
8.9 
8.8 
10.0 
(a) date of first application 
(b) date of necropsy 
(c) control animals 
(d) died 28 Mar - weight at necropsy on 29 Mar was 1.5 kg 
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. 
CUNtCAL OBSERVATKlNS 
RABBZTS 
One rabbit, A B ,  died during the course of the study. The animal was found dead in its cage 
on the seoond day following the completion of the third weekly application period. This animal 
had shown a poor appetite and marked loss of body weight for about a week before death. 
The skin lesions which developed on the back and sides as the result of Coolanol 15 appli- 
cation were similar in all animals, althougb there was some variation in the time of appearance. 
Some clinical improvement was generally noted over the weekends when no applications were 
made. 
Early in the study, a mild erythema was observed in the area of application in the afternoons. 
By the end of the fust week, all animals exhibited a dry, cracking skin. During the second week 
there was an increase in dryness and cracking and a thick white encrustation developed. In several 
unclipped areas where the coolano1 15 had spread, exudation also resulted in scab formation. 
At the end of the second week, the heavy white crust began to slough, exposing a thinly 
keratinized pliable surface with red lines where major cracks were present. The area gradually 
assumed a dry scaly appearance and by the end of the study, the skin had become somewhat 
thickened and again covered with a cracked white encrustation similar to that seen earlier. Early 
hair growth in the area of application was rather sparse, but by the end of the study, the three 
remaining animals had a dense hair growth. 
No lesions were observed on the two control animals. 
MONKEYS 
The response in monkeys to the cutaneous application of Coolano1 15 was less severe than 
that seen in rabbits. Three of the four monkeys exhibited minimal erythema and developed 
scurfy (dandruff-like) skin lesions that persisted throughout the study. At necropsy, the skin 
was dry, moderately scurfy, and areas of superficial desquamation were present. Areas of skin to 
skin contact, such as the inguinal and axdlary regions, were most severely affected. In general, 
there was also partial loss of hair on the extremities, and one animal exhibited localized alopecia 
of the head. 
One monkey, A43, was more severely affected. In addition to the scurfy skin, exudation and 
encrustation were observed in the inguinal and axillary regions at the end of the &st week. These 
lesions extended over the entire trunk during the second week and resulted in some cracking of 
the skin and scab formation. During this period, the animal's activity and appetite were some- 
what depressed. Moderate improvement was observed during the third week, although the skin 
appeared somewhat hyperkeratotic. At  necropsy, the skin on the back of the animal was dry, 
wrinkled, and scurfy. considerable desquamation and apparent mild exudation were observed on 
the chest, abdomen, and inguinal and axillary regions. 
No lesions were observed on the control animals. 
DOGS 
The severity of the reaction to coolanol 15 was variable in dogs. Dog B31 exhibited mild 
erythema following application and developed a scurfy skin which progressed to slight super- 
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ficial desquamation by the end of the second week. Some inflammation in the flank areas was also 
observed. At necropsy, the back and sides of the animal were moderately scurfy. 
Animal B61 was only slightly aected. Mild erythema was observed infrequently. A few 
papules developed on the back. At necropsy, the skin in the application area was only slightly 
scurfy with a few small scabs remaining in the area of the papules. 
Animal C60 developed a slight flaking of the skin during the first week of application. This 
increased moderately during the second week and was accompanied by inflammation and scab 
formation in the flank region. A few papules developed, but at necropsy the skin on the body 
was only slightly scurfy and there was a mild inflammatory process present in the flank regions. 
Dog C84 was most severely affected. During the first week the clipped area became slightly 
scurfy and the adjacent unclipped areas inflamed. The degree of involvement increased during 
the second week. Localized alopecia and desquamation were observed in the adjacent unclipped 
areas. The idammatory process was most severe in the flank and axillary regions and resulted 
in some exudation and encrustation. By the end of the second week, desquamation had occurred 
over one-third of the application area. Recently desquamated areas became quite reddened when 
the Coolanol 15 was applied. The entire area was involved the following week and had a quite 
scurfy appearance. The flank and tail-base area were markedly inflamed. At the time of necropsy, 
desquamation was still in progress and some inflammation was observed. 
Control animals showed no evidence of skin lesions at necropsy. 
PATHOLOGY 
RABBITS 
The primary effects of Coolanol 15 applications were observed in the skin. All animals de- 
veloped a moderate to marked degree of hyperkeratosis and desquamation of the stratum cor- 
neum. Lymphocytic infiltration of the dermal papillae and early suppuration and abscess forma- 
tion in the follicular areas were also observed. 
Kidney changes were found in three of the four animals. The animal that died had a moder- 
ate subacute infectious nephritis while the other two animals exhibited one or more of the fol- 
lowing: focal tubular degeneration, edema of the mucosa of the renal pelvis and proximal ureter, 
congestion of the medulla, and necrotic material in an occasional renal tubule. The two animals 
that were killed at the end of the study also had areas of tubular dilatation and atrophy and 
old bland scar. One had multiple epithelium-lined cortical cysts. These lesions were chronic in 
nature and apparently existed before the study. 
There was an indication of hyperchromaticity of glial cells, some satellitosis, and vacuoliza- 
tion of small neurons, especially in the cord sections, of the animal that died. Glial nodules were 
observed in the outer layer of the cerebral cortex in one of the control animals. The lesions in 
d e  control animal were compatible with an infection by Encephalitozoon sp. or similar organism. 
Some degenerative changes were observed in the livers of three of the four treated animals, 
and some lymphocytic and plasma cell infiltration was observed in the livers of control animals. 
Focal chronic idammatory lesions observed in the lungs and hearts of both experimental and 
control animals were not considered to be significant. 
The death of the one animal was apparently due to a septicemic disease, possibly introduced 
through a skin portal secondary to drying and cracking of the integumentary barrier. 
MONKEYS 
Mild to moderate hyperkeratosis of the skin with some lymphocytic and plasma cell acvumu- 
lations was observed in the four treated animals. One treated monkey, A43, had focal hepatocellu- 
lar necrosis associated with an idammatory response, focal pneumonitis, patchy pulmonary edema 
and blood in the larger bronchi. Focal inflammatory lesions in the lung, liver, and kidneys and mild 
hepatic cell vacuolization were not significantly ddferent in the experimental and control groups. 
No central nervous system lesions were present in either the treated or control animals. 
DOGS 
All anirnals in the treated group developed a mild hyperkeratosis. This was localized in the 
flank region in one of the animals. Microabscesses in the corium and subepidermal and perifol- 
licular infiltration of idammatory cells were observed in one of the animals, and an influx of 
subepidermal lymphocytic and epithelioid cells was found in the flank area of another. Hyperkera- 
tosis was also observed in one of the control animals. 
One treated animal (CM) showed focal hepatic inflammatory lesions containing polymor- 
phonuclear and lymphocytic cells, centrilobular swelling and eosinophilia of hepatic cell cytoplasm, 
and mild bile stasis. These changes were suggestive of regeneration in a continuing active hepa- 
titis. Focal inflammatory lesions were observed in the lungs and kidneys from both treated and 
control animals. 
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SECTION V 
Discussion 
The results of single intraperitoneal injections in mice and rats indicate that Coolanol 15 is 
relatively nontoxic. In those animals that received a lethal dose, death was somewhat delayed. 
Lesions observed indicate that the substance is rather irritating to the peritoneum. Large doses 
apparently have some toxic effects on the kidneys but the significance of other lesions observed 
was not established. Body weight loss could be attributed to the peritonitis which developed. 
No pathologic changes directly attributable to Coolanol 15 were observed in the central nervous 
system. One mouse did show a small glial focus in the cerebral cortex. Although the organism 
was not demonstrated, this was probably due to an infection by Encephalitozoon sp. or similar 
organism. 
The results of repeated subcutaneous injections in rabbits failed to reveal a significant toxic 
effect. Lesions observed were primarily associated with the irritant effect at the site of injection. 
Although some changes were observed in sections of spinal cord from one animal, they did not 
appear to be the primary result of Coolanol 15 administration. The inflammatory lung and liver 
lesions observed have been seen frequently in rabbits from other study groups and cannot be 
causally related to the administration of this compound. 
The primary clinical and pathologic effects of the cutaneous application were observed in 
the skin. Rabbits were the most severely and uniformly affected. All animals of this species de- 
veloped a dry cracked skin with a heavy white encrustation which sloughed, leaving a newly 
keratinized surface on which an encrustation again developed after further applications of Cool- 
anol 15. Drying and superficial flaking of the skin were the lesions most often observed in mon- 
keys. A partial loss of hair on the extremities was also noted. One monkey did develop a general- 
ized serous exudation and encrustation of the trunk with some cracking and scab formation. The 
degree of skin involvement in the dogs was also variable, ranging from mild erythema and some 
scurfiness to superficial desquamation over the entire dorsal and lateral surfaces of the trunk with 
moderate regional inflammation. The prominent histopathologic findings were hyperkeratosis, 
cellular infiltration in the dermal papillae, and perifollicular microabscess formation. The spon- 
taneous hyperkeratosis observed in one of the control dogs is not considered significant since 
this is occasionally seen in animals of this species. 
The dense hair growth observed in treated rabbits at necropsy was not apparent in control 
animals. The relationship between this dense hair growth and Coolanol 15 was not established 
since it was not confined strictly to the application area, and rabbits of the age used in this study 
may show rapid growth of “new hair.” 
Although the dog that was most severely affected was the only animal with a completely 
pigmented skin, there appeared to be no relationship between pigmentation and reaction to 
Coolanol 15. NO difference was observed in the reaction of pigmented and unpigmented areas 
on one of the other animals. 
Systemic effects were observed in only two of the treated animals. The rabbit that died 
exhibited a poor appetite and marked weight loss before death. Death, however, was apparently 
due to a septicemic disease which may possibly have been the result of the entrance of micro- 
organisms through the dry cracked skin. The monkey that developed the most severe skin lesions 
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and showed visceral lesions at necropsy exhibited a transient depression in motor activity and a p  
petite during the second week of the application period when the skin lesions were most acute. 
This may have been a reaction to the skin lesions or related to the pneumonitis and hepatitis 
seen at necropsy. The latter conditions are occasionally seen in control monkeys, and it is unlikely 
that they were related to the Coolano1 15 application. 
The results of body weight observations are inconclusive. Although there appears to be an 
adverse &e& on body weight, there is some inaccuracy inherent in the weighmg method used. 
The relationship between kidney and liver lesions observed in tbree of the four treated rab- 
bits and the application of Coolanol 15 is questionable. One of the animals involved was the one 
that died. In addition to the acute kidney changes observed in the other two animals, chronic 
lesions indicative of a preexisting disease process were present. 
It is unlikely that the liver lesions found in one of the treated dogs were related to the 
Coolanol 15. The changes were indicative of regeneration accompanying a continuing active 
hepatitis and were compatible with those occasionally seen in control animals from other study 
PUPS- 
No central nervous system lesions which could be attributed to the cutaneous application of 
Coolanol 15 were observed. Lesions were demonstrated in only one of the treated animals, the 
rabbit that died. These were nonspecific and apparently related to a septicemic disease rather 
than to the application of Coolano1 15. One of the control rabbits did show glial nodules in the 
cerebral cortex. Although the organism was not demonstrated, these lesions were compatible with 
an infedion by Encephalitozoon sp. or similar organism. 
The results of these studies do not substantiate the causal relationship between Coolanol 15 
and central nervous system lesions as previously reported. The failure to demonstrate lesions di- 
rectly attributable to Coolano115 in a variety of animals by several methods of exposure indicates 
that the changes reported in rabbits may have been due to a spontaneous disease process, possibly 
an infection by Encephalitozoon sp. 
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SECTION VI 
Conclusions 
Parenteral injections revealed that Coolanol 15 is relatively nontoxic. The intraperitoneal 
LDS0 for mice was found to be greater than 20.0 gm/kg (22.2 ml/kg) at 24 hours and 5.90 gm/kg 
(6.6 ml/kg ) at 7 and 14 days. Repeated subcutaneous injections in rabbits resulted primarily in 
localized reactions at injection sites. No central nervous system lesions directly attributable to 
Coolanol 15 were observed. 
The only effects which could be directly related to the repeated cutaneous application of 
Coolano1 15 involved the skin. Drying and encrustation and/or desquamation of the superficial 
layers of the skin were the principal lesions observed clinically while microscopic examination 
revealed varying degrees of hyperkeratosis and cellular infiltration. Rabbits were the most severely 
and uniformly affected. 
Neither the death of one rabbit nor the visceral lesions observed at necropsy could be directly 
attributed to the cutaneous application of Coolanol 15. Body weight data were inconclusive. The 
only central nervous system changes observed in a treated animal were those seen in the rabbit 
that died and were apparently due to a septicemic disease. Glial nodules were observed, how- 
ever, in one of the control rabbits. 
These studies failed to substantiate the previously reported changes in the central nervous 
system attributed to Coolanol 15. It is possible that the lesions observed in rabbits in the pre- 
vious study were due to a spontaneous infection by Encephalitozoon sp. or other similar organism. 
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